Scalper1 News
Medivation (MDVN) stock was up early Thursday on the company’s better-than-expected fourth-quarter earnings, as the biotech benefited from strong sales of its Xtandi prostate cancer drug. Reporting after Wednesday’s close, Medivation posted Q4 earnings of $1.96 a share, up from just 3 cents in Q4 2013 and well above consensus analyst estimates of $1.34. Revenue nearly tripled to $274.7 million, also above views. The San Francisco-based company Scalper1 News
Scalper1 News